The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
|Fatty Liver Hepatic Steatosis Diabetes Mellitus Liver Diseases||Drug: Probiotic-containing powder||Phase 1 Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||The Effect of a Probiotic on Hepatic Steatosis|
|Study Start Date:||July 2005|
|Estimated Study Completion Date:||February 2006|
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and is also common in diabetics; unfortunately, research on NAFLD has been limited. Safe, inexpensive, and well-tolerated treatments for NAFLD are needed. Recent studies indicate that probiotics help to improve fat breakdown in mice. This study will evaluate the efficacy of probiotic therapy to reduce fat accumulation in the livers of people with NAFLD and diabetes.
Participants in this study will be randomly assigned to receive either a probiotic-containing mixture or placebo once daily for 6 months. Blood tests, and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068094
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21205|
|Principal Investigator:||Steve Solga, MD||Johns Hopkins University|